Kite Pharma, Inc. 4
4 · Kite Pharma, Inc. · Filed May 18, 2016
Insider Transaction Report
Form 4
JENKINSON PAUL L
Chief Financial Officer
Transactions
- Award
Employee Stock Option (Right to Buy)
2016-05-16+125,000→ 125,000 totalExercise: $45.04Exp: 2026-05-15→ Common Stock (125,000 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the stock option vest and become exercisable on the first anniversary of the grant date identified in column 3, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.